Elmind Capital LP acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,000 shares of the biotechnology company's stock, valued at approximately $8,127,450,000. United Therapeutics comprises approximately 2.0% of Elmind Capital LP's holdings, making the stock its 16th biggest holding.
Several other hedge funds have also recently made changes to their positions in UTHR. Callan Family Office LLC acquired a new position in United Therapeutics in the 2nd quarter worth approximately $1,217,000. Leuthold Group LLC raised its stake in shares of United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company's stock valued at $5,200,000 after buying an additional 3,126 shares during the last quarter. UBS Group AG boosted its stake in shares of United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company's stock worth $110,045,000 after buying an additional 70,445 shares during the last quarter. Nicholas Investment Partners LP grew its holdings in United Therapeutics by 478.5% during the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company's stock worth $2,218,000 after acquiring an additional 3,766 shares during the period. Finally, M&T Bank Corp raised its position in United Therapeutics by 171.6% during the fourth quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company's stock valued at $1,531,000 after acquiring an additional 1,985 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on UTHR shares. Weiss Ratings raised shares of United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, August 13th. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. raised their target price on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $646.00.
Get Our Latest Research Report on UTHR
Insider Buying and Selling at United Therapeutics
In related news, CFO James Edgemond sold 10,000 shares of the company's stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at $10,311,581.28. This represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm's stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $545.83, for a total transaction of $5,185,385.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $22,113,210.79. This represents a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 434,075 shares of company stock worth $233,340,010. Insiders own 8.60% of the company's stock.
United Therapeutics Price Performance
Shares of NASDAQ:UTHR opened at $518.53 on Wednesday. The business's 50 day moving average price is $531.75 and its 200-day moving average price is $538.30. United Therapeutics Corporation has a 1 year low of $302.19 and a 1 year high of $609.35. The firm has a market capitalization of $22.24 billion, a price-to-earnings ratio of 18.55, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm's revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.41 EPS. On average, sell-side analysts expect that United Therapeutics Corporation will post 26.33 earnings per share for the current year.
United Therapeutics Company Profile
(
Free Report)
United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
